Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML

Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML

July 23, 2021 Leave a comment

During the last 50 years, there was a gentle enchancment within the therapy final result of acute myeloid leukemia (AML).…

Continue Reading →